Marker Therapeutics (MRKR) Stock Price, News & Analysis

Company Overview

Marker Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing T-cell therapies for cancer. The company’s platform is designed to produce multi-antigen-targeted T cells, which recognize several tumor-associated antigens rather than a single target. Marker Therapeutics has been developing these therapies for use in patients with hematologic malignancies and solid tumors.

The company’s investigational pipeline has included MT-601, an autologous multiTAA-specific T-cell therapy being evaluated for certain solid tumors, and MT-401, a related therapy developed for acute myeloid leukemia. These products are experimental and have not been approved for commercial use. Marker Therapeutics’ research and clinical-development activities are primarily focused in the United States.

Marker Therapeutics was previously known as TapImmune and adopted its current name in 2018 as it expanded its focus on multi-antigen T-cell therapies. The company is headquartered in Houston, Texas, and has been led by Peter Hoang, who has served as president and chief executive officer.

Key Stats

• Today's Range: $0.94 to $0.98
• 50-Day Range: $0.89 to $1.28
• 52-Week Range: $0.87 to $2.46
• Volume: 28,388 shs
• Average Volume: 200,759 shs
• Market Capitalization: $15.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Marker Therapeutics Stock Analysis - MarketRank™

Marker Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 448th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Marker Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Marker Therapeutics has a consensus price target of $10.00, representing about 952.5% upside from its current price of $0.95.

Amount of Analyst Coverage

Marker Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.64) to ($1.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Marker Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Marker Therapeutics is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Marker Therapeutics has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.12% of the float of Marker Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Marker Therapeutics has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Marker Therapeutics has recently increased by 61.43%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Marker Therapeutics does not currently pay a dividend.

Dividend Growth

Marker Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

Marker Therapeutics has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Marker Therapeutics this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for MRKR on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Marker Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Marker Therapeutics is held by insiders.

Percentage Held by Institutions

22.39% of the stock of Marker Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/11/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MRKR
• CIK: 1094038
• Web: www.markertherapeutics.com
• Phone: (713) 400-6400
• Fax: N/A
• Employees: 5
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Marker Therapeutics: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +952.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.16 million
• Net Margins: N/A
• Pretax Margin: -373.37%
• Return on Equity: -56.96%
• Return on Assets: -47.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.03
• Quick Ratio: 6.03

Sales & Book Value

• Annual Sales: $3.55 million
• Price / Sales: 4.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.01 per share
• Price / Book: 0.94

Miscellaneous

• Outstanding Shares: 16,670,000
• Free Float: 15,723,000
• Market Cap: $15.84 million
• Optionable: Not Optionable
• Beta: 1.65